Navigation Links
Stemline Therapeutics Raises $12.5 Million
Date:4/9/2008

Proceeds to advance oncology therapeutics targeting cancer stem cells

NEW YORK, April 9, 2008 /PRNewswire/ -- Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company and a leading developer of oncology compounds directed to cancer stem cell targets, today announced that it has completed a $12.5 million round of financing with healthcare funds managed by Pequot Capital Management, Inc.

Stemline's CEO, Ivan Bergstein, MD, said. "We are very pleased to have consummated this transaction with a fund of this caliber. The capital provides us with significant runway to advance our clinical program, while continuing to build out our pipeline, discovery platform, and comprehensive IP estate. Moreover, this financing allows us to continue to strengthen our leadership position in the rapidly emerging cancer stem cell field."

About Stemline Therapeutics, Inc.

Stemline Therapeutics, Inc. is a clinical stage biotechnology company developing novel oncology compounds directed to cancer stem cell targets. Stemline's lead compound, SL-401, targets the interleukin-3 receptor present on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells. SL-401 has demonstrated single agent anti-tumor activity at tolerable doses in a multi-center Phase I human trial. In addition, Stemline is developing a portfolio of compounds directed at this and other high value cancer stem cell targets of a variety of hematological and solid cancers. Stemline has also built a robust discovery platform called "StemScreen(R)" which the Company has utilized to identify multiple compounds that target and impair cancer stem cells. For more information, please visit the Company's website at http://www.stemline.com.


'/>"/>
SOURCE Stemline Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
2. Amsterdam Molecular Therapeutics Part of Next Biotech Index
3. Sirion Therapeutics Highlights Pivotal Trial Results of Durezol(TM) at the American Society of Cataract and Refractive Surgery Annual Symposium
4. Alba Therapeutics Announces Appointment of Bruce A. Peacock as its Chief Executive Officer
5. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
6. DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
7. ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
8. Mercury Therapeutics Patents Filed
9. Cell Therapeutics, Inc. Announces Filing of Form 10-K
10. Vicus Therapeutics Announces Participation at 15th International Molecular Medicine Tri-Conference
11. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... ... , ... At its national board meeting in North Carolina, ARCS® Foundation ... of Physics and Astronomy, has been selected for membership in ARCS Alumni Hall ... 2015 Breakthrough Prize in Fundamental physics for the discovery of the accelerating expansion of ...
(Date:10/7/2017)... , ... October 06, 2017 ... ... experience providing advanced instruments and applications consulting for microscopy and surface analysis, ... in application consulting, Nanoscience Analytical offers a broad range of contract analysis ...
(Date:10/6/2017)... Mass. (PRWEB) , ... October 06, 2017 , ... ... female entrepreneurship within the healthcare and technology sector at their fourth annual Conference ... panels featuring 30 inspiring speakers and the ELEVATE pitch competition showcasing early stage ...
(Date:10/5/2017)... ... 2017 , ... Understanding the microbiome, the millions of bacteria that live in ... Are My Future, the newest exhibit on display at the University City Science Center’s ... through the lens of the gut microbiome. , Gut Love opens October 12, ...
Breaking Biology Technology:
(Date:5/23/2017)... -- Hunova, the first robotic gym for the rehabilitation and functional motor sense ... Genoa, Italy . The first 30 robots will be available ... USA . The technology was developed and patented at the IIT ... Movendo Technology thanks to a 10 million euro investment from entrepreneur Sergio ... ...
(Date:4/24/2017)... , April 24, 2017 ... and partner with  Identity Strategy Partners, LLP (IdSP) ... "With or without President Trump,s March 6, 2017 ... Terrorist Entry , refugee vetting can be instilled with ... resettlement. (Right now, all refugee applications are suspended ...
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced ... will feature emerging and evolving technology through ... Innovation Summits will run alongside the expo portion of ... sessions, panels and demonstrations focused on trending topics within ... advanced design and manufacturing event will take place June ...
Breaking Biology News(10 mins):